Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Editas Medicine (EDIT)

$25.64 0.28 (1.10%)

17:58 EDT EDIT Stock Quote Delayed 15 Minutes

Volume:

Previous Close $25.64

Market Cap 1.22B

PE Ratio -9.16

EPS -2.8

Volume (Avg. Vol.) 690,800

Day's Range 25.44 - 26.06

52-Week Range 17.80 - 33.80

Dividend & Yield N/A (N/A)

EDIT Stock Predictions, Articles, and Editas Medicine News

From InvestorPlace
From the Web

3 Biotech Stocks That Are Set for a Breakthrough

By Matt McCall, Editor, MoneyWire Feb 1, 2019

If you're looking for biotech stocks to buy with massive breakthrough potential in gene editing, then these three are kings among the rest.

Gene Editing is a Major Technology to Watch

By Matt McCall, Editor, MoneyWire Aug 27, 2018

Gene-editing technology is going to be a game-changer in the future, which means the time to invest in CRISPR stocks is now.

Whole Foods Market, Inc. (WFM) and Xtant Medical Holdings Inc (XTNT) Lead 13 Activist Investment Filings

By Fintel May 31, 2017

13G and 13D filings are windows into activist investor activity. Latest filings include Whole Foods Markets, Inc., and these 12 other stocks

Editas Medicine, Inc. (EDIT) Q2 2019 Earnings Call Transcript

From The Motley Fool Aug 8, 2019

EDIT earnings call for the period ending June 30, 2019.

Editas Medicine Inc (EDIT) Receives a Hold from J.P. Morgan

From Smarter Analyst Aug 7, 2019

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Editas Medicine Inc (EDIT) yesterday and set a price target of $30. The company's shares

Editas Medicine Inc (EDIT) Received its Third Buy in a Row

From Smarter Analyst Aug 7, 2019

After Raymond James and Cowen & Co. gave Editas Medicine Inc (NASDAQ: EDIT) a Buy rating last month, the company received another Buy, this time from

Editas Medicine Inc (EDIT) Gets a Buy Rating from Cowen & Co.

From Smarter Analyst Aug 7, 2019

In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Editas Medicine Inc (EDIT). The company's shares closed

The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

From Benzinga Aug 6, 2019

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech...

40 Healthcare Stocks Moving In Thursday's After-Market Session

From Benzinga Aug 2, 2019

Gainers Aphria, Inc. (NYSE: APHA) shares moved upwards by 32.0% to $6.88 during Thursday's after-market session. The market cap stands at $1.3 B. According to the most...

Navellier Ratings

Powered by Portfolio Grader

Total Grade

C

Hold

Free Report

10 Stocks Set for Monster Growth

He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!

Download your FREE COPY!